DelveInsight’s “Insulin Resistance Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Insulin Resistance, historical and forecasted epidemiology as well as the Insulin Resistance market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Insulin Resistance market report provides current treatment practices, emerging drugs, Insulin Resistance market share of individual therapies, and current and forecasted Insulin Resistance market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current Insulin Resistance treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Insulin Resistance market.
Some of the Key Facts of the Insulin Resistance Market Report:
-
The sociodemographic and psychobiologic features of the sample are summarized while metabolic and anthropometric aspects are presented. A total of 2026 individuals have studied: 52.10% females and 47.90% males. The mean age was years (years for women, years for men.
Got queries? Click here to learn more about Insulin Resistance Market Insights
Insulin Resistance Overview
an impaired response of the body to insulin, resulting in elevated levels of glucose in the blood (a key component of type 2 diabetes and metabolic syndrome).”obesity has been linked to the development of insulin resistance and osteoarthritis”
Insulin Resistance Epidemiological Insights
-
The prevalence of IR was 46.5% in the general population, with 46.7% in women and 46.4% in men. On the other hand, illustrates the prevalence of IR by age groups: A significantly greater proportion of IR was found in the groups aged 30–59 years (49.7%, ) and ≥60 years (49.8%, ), in comparison to individuals aged
-
When assessing the epidemiologic behavior of IR according to sociodemographic factors, an association was found only in regard to marital status, with a significantly greater proportion of IR subjects among married individuals (51.5% versus 48.5% individuals with HOMA2-IR < 2).
-
Regarding smoking habits, no link was found with the presence of IR. Nevertheless, we observed a greater proportion of IR subjects among past smokers (51.9% versus 48.1% without IR; ). Conversely, the absence of IR was prevalent among nonsmokers (55.2% versus 44.8% with IR; ). With respect to alcohol intake and IR (Figure, no statistically significant association was found.
-
Similarly, no link was ascertained between IR and PA in the home, work (; ), and transport (; ) domains (Table 5). However, a significant association was ascertained between the presence of IR and leisure-domain PA, with a higher proportion of non-IR individuals in the high and very high PA categories in this domain (61.3%, and 65.5%, resp., versus IR subjects; ).
Insulin Resistance Epidemiological Segmentation
-
Total Insulin Resistance prevelant cases.
-
Total Insulin Resistance cases based on psychobiologic habits.
-
Total Insulin Resistance cases based on metabolic characters.
-
Total Insulin Resistance cases based on age group
Insulin Resistance Market Outlook
The Insulin Resistance market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Insulin Resistance market trends by analyzing the impact of current Insulin Resistance therapies on the market, unmet needs, drivers and barriers, and demand for better technology.
This segment gives a thorough detail of the Insulin Resistance market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Insulin Resistance market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the Insulin Resistance market in 7MM is expected to witness a major change in the study period 2019-2032.
Learn more by requesting for sample @ Insulin Resistance Market Landscape
Insulin Resistance Key Companies
-
Novartis
-
Astrazeneca
-
GSK
-
Genentech
-
Orso Bio Inc
-
And many others
Insulin Resistance Key Therapies
-
Empagliflozin
-
TLC-3595
-
Physostigmine
-
Avandio
-
BFKB8488A
Table of Contents
-
Key Insights
-
Report Introduction
-
Executive Summary of Insulin Resistance
-
Disease Background and Overview
-
Epidemiology and patient population
-
Insulin Resistance Emerging Therapies
-
Insulin Resistance Market Outlook
-
Market Access and Reimbursement of Therapies
-
Appendix
-
Insulin Resistance Report Methodology
-
DelveInsight Capabilities
-
Disclaimer
-
About DelveInsight
Click here to read more about Insulin Resistance Market Insights
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/